Severin Schwan, CEO of Swiss pharma giant Roche, has warned that the demand for Covid-19 tests still outstrips supply, making more broad-based testing challenging.
This content was published on
2 minutes
Keystone-SDA/jdp
“It is very likely that vaccines will only be broadly available later next year so I expect the demand to outstrip supply for a number of months and even beyond then,” Schwan said in a briefing to the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA).
Since the start of the pandemic, Roche has been a major developer of tests to detect and diagnose Covid-19. It has received Emergency Use Authorization from the US authorities for its PCR diagnostic as well as antibodies tests, while it has also developed a test to differentiate between flu and Covid-19 strains.
Schwan said it will be important even beyond the pandemic to use testing to distinguish between diseases showing similar symptoms, such as influenza.
Targeted vs mass testing
While some neighbouring countries such as Austria have pushed for more widespread testing, Switzerland has up to now encouraged testing only for people showing Covid-19 symptoms. A few days ago, Graubünden became the first canton to launch a pilot programme to conduct mass testing of residents as part of its measures to shore up the ski season.
Schwan acknowledged that testing more broadly offers an opportunity to open up the economy but said the quantities are simply not available. “It is important that testing is prioritised. First, we need to take care of symptomatic patients and healthcare workers. Only if volumes allow for broader testing, should we go in this direction,” he said during the briefing.
SWISS international airlines announced at the end of September that it would start testing passengers on certain flights with tests developed by Roche.
Although PCR tests remain the gold standard in Covid-19 testing, Schwan said that rapid antigen tests can be produced at much larger scale – which could open the door for broader coverage of the population.
Popular Stories
More
Multinational companies
Azeri fossil-fuel cash cow brings controversy to Switzerland
Swiss price watchdog slams excessive prices for generic medicines
This content was published on
The cheapest generic medicines available in Switzerland are more than twice as expensive as in other countries, according to a study by the Swiss price watchdog.
Nature should not figure in net zero calculations: academic study
This content was published on
The natural removal of CO2 from the atmosphere by forests or oceans should not be included in the net-zero balance of climate protection measures, argue researchers.
This content was published on
None of the 15 major Swiss retail banks is meeting international climate and biodiversity targets, according to a ranking by WWF Switzerland.
This content was published on
Nestlé's new CEO Laurent Freixe, has presented plans for the future of the world's largest food company, after his first few weeks in office.
Swiss foreign minister calls on Moscow to end Ukraine war
This content was published on
It's high time Moscow ended its war against Ukraine, Swiss foreign minister Ignazio Cassis tells the UN Security Council.
This content was published on
The only alternative to the UN Palestinian agency’s work in Gaza is to allow Israel to run services there, Philippe Lazzarini, UNRWA Commissioner-General, told reporters in Geneva on Monday.
Study reveals food culture differences between Switzerland and neighbours
This content was published on
Three-quarters of Swiss people consider eating to be a pleasurable, social activity, a new survey reveals. Healthy eating, however, plays a much less important role, it found.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Roche poised to launch mass Covid testing
This content was published on
Swiss drug firm Roche says it is to launch a new Covid-19 antigen test before the end of the year, allowing faster, higher-volume testing.
This content was published on
Swiss firm Roche receives US Emergency Use Authorization for a test to quickly detect whether a patient has Covid-19 or one of two forms of flu.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.